10-Q · May 6, 2026
In Q1 2026, 908 Devices (MASS) reported revenues of $13.4 million, marking a 14% increase compared to $11.8 million in Q1 2025, although it resulted in a net loss of $12.0 million, up from $9.8 million year-over-year.…
Earnings analysis · 10-Q
MASS earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
908 Devices delivered $16.074 million of revenue, beating the $15.3352 million consensus estimate, and raised the low end of full-year 2026 revenue guidance to $68.0 million. However, diluted EPS of negative $0.32…
Read full summary
908 Devices delivered $16.074 million of revenue, beating the $15.3352 million consensus estimate, and raised the low end of full-year 2026 revenue guidance to $68.0 million. However, diluted EPS of negative $0.32 missed the negative $0.14 estimate, while net loss from continuing operations was $11.894 million. NIRLAB results were included following the May 4, 2026 acquisition, but the filing provides no material changes to previously disclosed risk factors and does not provide sufficient information to assess current-quarter margins, balance-sheet trends, or cash flow.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.32
What stood out
-
Revenue Beat Estimates
Revenue was $16.074 million, approximately $0.739 million or 4.8% above the $15.3352 million consensus estimate. The filing's reported revenue was also above the $13 million shown for 2026 Q1 in the provided quarterly history.
-
Revenue Outlook Raised
The company raised the low end of full-year 2026 revenue guidance by $1.0 million, to $68.0 million-$70.0 million from $67.0 million-$70.0 million previously.
-
NIRLAB Results Included
NIRLAB was acquired on May 4, 2026, and its results were included in the unaudited consolidated financial statements for the three and six months ended June 30, 2026.
-
Disclosure Controls Effective
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
What to watch
-
EPS Miss and Persistent Losses
Net loss from continuing operations was $11.894 million, and diluted EPS of negative $0.32 missed the negative $0.14 consensus estimate by $0.18, indicating continued earnings volatility despite the revenue beat.
-
Acquisition Integration Risk
The May 4, 2026 NIRLAB acquisition adds integration and control complexity; management stated it intends to exclude NIRLAB from its internal-control evaluation as of December 31, 2026.
-
Executive Share-Sale Plans
Two executives adopted Rule 10b5-1 trading plans covering potential sales of up to 16,459 shares for the CFO and 44,251 shares for the Senior Vice President of Sales & Product Marketing. The plans expire on August 10, 2027 and December 31, 2026, respectively.
Management's outlook
Full-year 2026 revenue outlook was raised at the low end to $68.0 million-$70.0 million from $67.0 million-$70.0 million previously, implying approximately 21%-25% year-over-year growth. No quantitative EPS outlook was provided.
Earlier filings 4
10-K · March 9, 2026
908 Devices positions itself as a provider of handheld, point-of-need chemical analysis leveraging proprietary microscale mass spectrometry (HPMS) and complementary optical spectroscopy to address health, safety and…
10-Q · November 10, 2025
908 Devices reported Q3 2025 revenue of $14,005,000, a slight decline from $14,519,000 in Q3 2024, but an increase from $13,000,000 in Q2 2025. Despite reporting a loss of $14,982,000, an improvement from a larger loss…
10-Q · August 5, 2025
908 Devices reported Q2 revenue of $13,035,000 (up from $11,462,000 in Q2 2024, +13.8%) and gross profit of $6,373,000 (gross margin 48.9%). The company recorded a loss from continuing operations of $12,908 (net loss…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.